- Free from Publisher T Heise, S Bott, C Tusek, JA Stephan, T … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—For the INH and SC groups, mean (±SD) IAB levels were 3.5 ± 3.9 and
2.6 ± 4.1 μU/ml at baseline, respectively, compared with 101.4 ± 140.4 and
4.3 ± 9.4 μU/ml at week 24. At week 24, the changes from baseline were ... Cited by 80 - Related articles - BL Direct - All 6 versions
- ►endojournals.org SE Fineberg, T Kawabata, D Finco-Kent, C Liu … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Research Design and Methods: Insulin antibody data from initial phase II/III
trials were analyzed comparing the efficacy and safety of inhaled insulin with
various agents, including sc insulin. Additionally, data from a 24-month ... Cited by 119 - Related articles - All 6 versions
- ►diabetesjournals.org N Freemantle, L Blonde, D Duhot, M Hompesch … - Diabetes Care, 2005 - Am Diabetes Assoc Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment
of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin
formulation is delivered by aerosol, permitting the noninvasive ... Cited by 102 - Related articles - All 7 versions
- ►ucalgary.ca [PDF] - Free from Publisher JS Skyler, RS Weinstock, P Raskin, JF Yale, E … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Mean glycosylated hemoglobin (A1C) decreased comparably from baseline
in the inhaled and subcutaneous insulin groups (−0.3 and −0.1%,
respectively; adjusted difference −0.16% [CI −0.34 to 0.01]), with a ... Cited by 104 - Related articles - BL Direct - All 10 versions
- Free from Publisher RA DeFronzo, RM Bergenstal, WT Cefalu, J … - Diabetes Care, 2005 - cat.inist.fr OBJECTIVE- Effective type 2 diabetes management requires prompt intervention if
glycemic control is not achieved by nonpharmacological means. This study
investigates whether inhaled insulin(INH; Exubera) can achieve target ... Cited by 73 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org K Rave, S Bott, L Heinemann, S Sha, RHA … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—INH had a faster onset of action than both RHI and ILP, as indicated
by shorter time to early half-maximal effect (32 vs. 48 and 41 min,
respectively; P < 0.001 for IHN vs. RHI and P < 0.05 for IHN vs. ILP). Time ... Cited by 112 - Related articles - All 7 versions
- ►annals.org [PDF] J Rosenstock, B Zinman, LJ Murphy, SC … - Annals of internal medicine, 2005 - Am Coll Physicians Inhaled Insulin Improves Glycemic Control When Substituted for or ... Added to
Oral Combination Therapy in Type 2 Diabetes ... Julio Rosenstock, MD; Bernard
Zinman, MD; Liam J. Murphy, MD; Stephen C. Clement, MD; Paul Moore, MD; C. ... Cited by 163 - Related articles - BL Direct - All 8 versions
- Free from Publisher K Hermansen, T Ronnemaa, AH Petersen, S … - Diabetes Care, 2004 - 万方数据资源系统 OBJECTIVE:-To compare the glycemic control of inhaled insulin via the AERx
insulin diabetes management system (iDMS) with that of subcutaneous (SC)
insulin, both combined with NPH insulin at bedtime, in patients with type 2 ... Cited by 79 - Related articles - BL Direct - All 5 versions
- ►colfar.com [PDF] - Free from Publisher PA Hollander, L Blonde, R Rowe, AE Mehta, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS— HbA 1c decreased similarly in the inhaled (−0.7%) and subcutaneous
(−0.6%) insulin groups (adjusted treatment group difference: −0.07%, 95% CI
−0.32 to 0.17). HbA 1c <7.0% was achieved in more patients receiving ... Cited by 237 - Related articles - BL Direct - All 21 versions
- ►diabetesjournals.org J Rosenstock, JC Cappelleri, B Bolinder, RA … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Of the 60 patients who received inhaled insulin during the parent
studies, 85.0% (n = 51) chose to continue treatment, 13.3% (n = 8) switched to
subcutaneous insulin, and 1.7% (n = 1) did not continue. Of the 61 patients ... Cited by 132 - Related articles - BL Direct - All 12 versions
